This biotech making precision medicines for cancer could nearly triple, says JPMorgan
JPMorgan analyst Priyanka Grover initiated coverage of Kura Oncology with an overweight rating and a price target of $30, implying roughly 180 percent upside. The bank cited the company's growing cancer drug sales and a promising pipeline of precision oncology treatments as key drivers. The bullish call underscores continued investor confidence in targeted cancer therapeutics.
The Atomic take
JPMorgan's $30 target rests on two concrete legs: Kura's climbing cancer drug sales and a precision oncology pipeline that targets specific tumor mutations rather than treating broadly. For longevity watchers, the interesting part is whether these targeted therapeutics can turn historically fatal cancers into managed conditions. Watch for the revenue trajectory on Kura's approved drugs and clinical readouts from the pipeline, since Grover's 180 percent upside assumes both keep delivering.
Read the full story at CNBC →Know where humanity is headed.
Five forces, one investment thesis a day. Free, every weekday morning.
Get The Atomic Five